Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Personalized DC vaccine in TMB-high advanced solid tumors
NCT03671720Phase 1Withdrawn
- Sponsor
- Capital Medical University
- Start
- Sep 2018
- Primary completion
- Dec 2021
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial in solid tumor, sponsored by Capital Medical University. Primary endpoint: Treatment-related adverse events at 12 months. Planned start Sep 2018; status: withdrawn.
02
Conditions
solid tumor
Beyond the preview
Go deeper on NCT03671720.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03671720.